Rafi Ahmed
Auto-generated profile, based on publicly available information

Rafi Ahmed

Emory Vaccine Center, Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2016 in Nature
Verified
Journal Article
Closed access
PDF file
SISe Jin Im
Se Jin Im
MHMasao Hashimoto
Masao Hashimoto
MGMichael Y. Gerner
Michael Y. Gerner
JLJunghwa Lee
Junghwa Lee
HKHaydn T. Kissick
Haydn T. Kissick
RARafi Ahmed
Rafi Ahmed

31 March 2017 in Science
Verified
Journal Article
Closed access
PDF file
AKAlice O. Kamphorst
Alice O. Kamphorst
AWAndreas Wieland
Andreas Wieland
TNTahseen Nasti
Tahseen Nasti
SYShu Yang
Shu Yang
RZRuan Zhang
Ruan Zhang
RARafi Ahmed
Rafi Ahmed
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.

2 August 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HJHyun-Tak Jin
Hyun-Tak Jin
AAAna C. Anderson
Ana C. Anderson
WTWendy G. Tan
Wendy G. Tan
EWErin E. West
Erin E. West
SHSang-Jun Ha
Sang-Jun Ha
RARafi Ahmed
Rafi Ahmed
Inhibitory receptors play a crucial role in regulating CD8 T-cell function during chronic viral infection. T-cell Ig- and mucin-domain–containing molecule–3 (Tim-3) is well known to negatively regulate T-cell responses, but its role in CD8 T-cell exhaustion during chronic infection in vivo remains unclear. In this study, we document coregulation of CD8 T cell exhaustion by Tim-3 and PD-1 during chronic lymphocytic choriomeningitis virus infection. Whereas Tim-3 was only transiently expressed by CD8 T cells after acute infection, virus-specific CD8 T cells retained high Tim-3 expression throughout chronic infection. The majority (approximately 65% to 80%) of lymphocytic choriomeningitis virus–specific CD8 T cells in lymphoid and nonlymphoid organs coexpressed Tim-3 and PD-1. This coexpression of Tim-3 and PD-1 was associated with more severe CD8 T-cell exhaustion in terms of proliferation and secretion of effector cytokines such as IFN-γ, TNF-α, and IL-2. Interestingly, CD8 T cells expressing both inhibitory receptors also produced the suppressive cytokine IL-10. Most importantly, combined blockade of Tim-3 and PD-1 pathways in vivo synergistically improved CD8 T cell responses and viral control in chronically infected mice. Taken together, our study defines a parameter for determining the severity of CD8 T cell dysfunction and for identifying virus-specific CD8 T cells that produce IL-10, and shows that targeting both PD-1 and Tim-3 is an effective immune strategy for treating chronic viral infections.

26 April 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
AKAlice O. Kamphorst
Alice O. Kamphorst
RPRathi N. Pillai
Rathi N. Pillai
SYShu Yang
Shu Yang
TNTahseen H. Nasti
Tahseen H. Nasti
RARama S. Akondy
Rama S. Akondy
SRSuresh S. Ramalingam
Suresh S. Ramalingam
Exhausted T cells in chronic infections and cancer have sustained expression of the inhibitory receptor programmed cell death 1 (PD-1). Therapies that block the PD-1 pathway have shown promising clinical results in a significant number of advanced-stage cancer patients. Nonetheless, a better understanding of the immunological responses induced by PD-1 blockade in cancer patients is lacking. Identification of predictive biomarkers is a priority in the field, but whether peripheral blood analysis can provide biomarkers to monitor or predict patients’ responses to treatment remains to be resolved. In this study, we analyzed longitudinal blood samples from advanced stage non–small cell lung cancer (NSCLC) patients (n = 29) receiving PD-1–targeted therapies. We detected an increase in Ki-67+ PD-1+ CD8 T cells following therapy in ∼70% of patients, and most responses were induced after the first or second treatment cycle. This T-cell activation was not indiscriminate because we observed only minimal effects on EBV-specific CD8 T cells, suggesting that responding cells may be tumor specific. These proliferating CD8 T cells had an effector-like phenotype (HLA-DR+, CD38+, Bcl-2lo), expressed costimulatory molecules (CD28, CD27, ICOS), and had high levels of PD-1 and coexpression of CTLA-4. We found that 70% of patients with disease progression had either a delayed or absent PD-1+ CD8 T-cell response, whereas 80% of patients with clinical benefit exhibited PD-1+ CD8 T-cell responses within 4 wk of treatment initiation. Our results suggest that peripheral blood analysis may provide valuable insights into NSCLC patients’ responses to PD-1–targeted therapies.

10 January 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JWJens Wrammert
Jens Wrammert
DKDimitrios Koutsonanos
Dimitrios Koutsonanos
GLGui-Mei Li
Gui-Mei Li
SESrilatha Edupuganti
Srilatha Edupuganti
JSJianhua Sui
Jianhua Sui
PWPatrick Wilson
Patrick Wilson
The 2009 pandemic H1N1 influenza pandemic demonstrated the global health threat of reassortant influenza strains. Herein, we report a detailed analysis of plasmablast and monoclonal antibody responses induced by pandemic H1N1 infection in humans. Unlike antibodies elicited by annual influenza vaccinations, most neutralizing antibodies induced by pandemic H1N1 infection were broadly cross-reactive against epitopes in the hemagglutinin (HA) stalk and head domain of multiple influenza strains. The antibodies were from cells that had undergone extensive affinity maturation. Based on these observations, we postulate that the plasmablasts producing these broadly neutralizing antibodies were predominantly derived from activated memory B cells specific for epitopes conserved in several influenza strains. Consequently, most neutralizing antibodies were broadly reactive against divergent H1N1 and H5N1 influenza strains. This suggests that a pan-influenza vaccine may be possible, given the right immunogen. Antibodies generated potently protected and rescued mice from lethal challenge with pandemic H1N1 or antigenically distinct influenza strains, making them excellent therapeutic candidates.

1 December 2019 in Immunity
Verified
Journal Article
Closed access
WHWilliam H. Hudson
William H. Hudson
JGJulia Gensheimer
Julia Gensheimer
MHMasao Hashimoto
Masao Hashimoto
AWAndreas Wieland
Andreas Wieland
RVRajesh M. Valanparambil
Rajesh M. Valanparambil
RARafi Ahmed
Rafi Ahmed